GlucoTrack (GCTK) Surges 117% on 391235% Spike in Trading Volume Ranks 108th in Daily Trading Activity

, 2025, . , reflecting heightened investor interest in its market position.

The sharp price movement aligns with recent developments in the company's product pipeline and regulatory progress. Analysts noted that a key partnership announcement and anticipated FDA clearance for a next-generation glucose monitoring device contributed to the rally. These updates position the firm to expand its market share in the diabetes management sector, where demand for non-invasive technologies remains robust.

Operational metrics also showed improvement, . The revised forecasts, combined with strategic cost-cutting measures, reinforced investor confidence in its ability to scale operations profitably.

To build an accurate back-test, the following parameters must be confirmed: 1. **Universe**: Define the stock pool (e.g., all U.S. common stocks or a subset like the S&P 500). 2. ** & prices**: Specify whether trades occur based on prior-day volume, next-day open/close prices, or a custom schedule. 3. **Weighting**: Choose between equal-weighting or market-cap-weighting for the 500-stock basket. 4. **Constraints**: Acknowledge the current back-testing engine's limitations for multi-asset portfolios and confirm feasibility of custom data aggregation.